GTx

About GTx

GTx, Inc. was a biopharmaceutical firm established in Memphis, Tennessee, in September 1997, initially under the name Genotherapeutics before rebranding in 2001. The company was the creation of Mitchell S. Steiner, a board-certified urologist with an extensive academic and research background at institutions like The Johns Hopkins Hospital and the University of Tennessee, and Marc S. Hanover, whose expertise lay in finance, banking, and private equity. Dr. Steiner's deep scientific and clinical knowledge, particularly in urology and oncology, complemented Mr. Hanover's financial and operational acumen, which was honed as a senior vice president at National Bank of Commerce and as a founder of a private equity firm.

The company's core business was the discovery and development of small molecules targeting hormone pathways, specifically focusing on selective androgen receptor modulators (SARMs) and selective estrogen receptor modulators (SERMs). This strategic focus aimed to address serious medical conditions, primarily in the realms of cancer and men's health. GTx's business model revolved around advancing these proprietary and licensed compounds through the rigorous and capital-intensive clinical trial process to gain regulatory approval and achieve commercialization. Revenue generation was anticipated through drug sales, partnerships, and licensing agreements. A key part of their strategy involved in-licensing promising compounds, such as the SARM portfolio from the University of Tennessee Research Foundation, which included enobosarm (also known as ostarine).

GTx's pipeline was led by enobosarm, a SARM intended to treat conditions like muscle wasting in cancer patients and, later, stress urinary incontinence. Another significant candidate was toremifene, a SERM developed for preventing prostate cancer and bone loss in men undergoing androgen deprivation therapy. The company achieved several milestones, including a public listing via an IPO in February 2004 and a substantial exclusive license agreement with Merck for its SARM program in 2007, which brought in a $40M upfront fee and $30M in equity investment. However, the company also faced significant setbacks. The FDA rejected an application for toremifene in 2009, and partnerships with Ipsen and Merck were subsequently terminated. A major turning point occurred in August 2013 when enobosarm failed in two Phase III clinical trials for treating muscle wasting, leading to a significant workforce reduction and the resignation of co-founder Mitch Steiner the following year.

After subsequent clinical trial failures and strategic shifts, GTx's journey as an independent entity concluded in June 2019. The company executed a reverse merger with Oncternal Therapeutics, a private clinical-stage oncology company. The combined entity continued under the Oncternal Therapeutics name, retaining GTx's Nasdaq listing but shifting focus to Oncternal's oncology pipeline, which was supplemented by GTx's preclinical Selective Androgen Receptor Degrader (SARD) program. No employees from GTx were retained in the new organization.